Continuing Professional Development Resources

---

"Consumer and clinician summary guides to help families and clinicians work together to make important decisions about how to treat and manage Autism Spectrum Disorders"

Agency for Healthcare Research and Quality (AGRQ), United States Department of Health & Human Services 

For Families: "Therapies for Children with Autism Spectrum Disorders, A Review of the Research for Caregivers"
http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=709

For Clinicians: "Comparative Effectiveness of Therapies for Children with Autism Spectrum Disorders"
http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=708

"Comparative Effectiveness of Therapies for Children with Autism Spectrum Disorders" Continuing Education Module"
http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displaycmeactivity&activityID=292&cmepage=cme_info&PCem=EN

Original release date: June 2011. Valid for credit through June 2014.

Target Audience:  This CME activity is designed to meet the educational needs of primary care and internal medicine physicians, as well as health care professionals who treat children with autism spectrum disorders.

Educational Objectives: At the conclusion of this activity, the participant should be able to:

• Describe the effectiveness of medical, behavioral, and educational interventions used to treat children with autism spectrum disorders.
• Describe the safety of medical interventions used to treat children with autism spectrum disorders.
• Identify gaps in the current evidence base regarding the comparative effectiveness and safety of therapies used to treat children with autism spectrum disorders.

---

Educational Resources & Sites: http://www.ddd.uwo.ca/resources/educational.html

---

EP Live Online
EP Global Communications Inc. (publisher of Exceptional Parent Magazine) in association with Vemics, Inc.
Archived Events: http://www.epliveonline.com/eplive-archive3.html

---

Events: http://www.ddd.uwo.ca/events.html

---

Medscape CMEs:

"Lennox-Gastaut Syndrome Across the Lifespan: Best Practices for Pre- and Post-Adolescent Care" CME
http://www.medscape.org/viewarticle/758832
Wheless, J.W. and Conry, J.A.
CME Released: 02/24/2012; Valid for credit through 02/24/2013
Medscape Education Neurology & Neurosurgery

Target Audience: Neurologists

Upon completion of this activity, participants will be able to:

1. Identify changes in seizure patterns as well as personal and physical needs in children with LGS as they progress through adolescence and adulthood
2. Identify barriers to transitioning the care of patients with LGS from the pediatrician to the adult neurologist and outline strategies to ensure continuity of care as patients age
3. Propose treatment plans to optimize quality of life and treatment outcomes of children and adults with LGS

"Study Confirms No Safe Amount of Alcohol Intake During Pregnancy" CME/CE
http://www.medscape.org/viewarticle/757668
Brooks, M. and Lie, D.
CME/CE Released: 01/30/2012; Valid for credit through 01/30/2013
Medscape Education Clinical Briefs

Target Audience: This article is intended for primary care clinicians, obstetricians, and other specialists who care for pregnant women.

Upon completion of this activity, participants will be able to:

1. Describe the association between the dose of alcohol exposure during pregnancy and the risks for dysmorphism and growth deficiencies in infants.
2. Describe the association between timing of alcohol exposure during pregnancy and dysmorphism, low birth weight and length, and small head circumference.

“Prenatal alcohol exposure patterns and alcohol-related birth defects and growth deficiencies: a prospective study”
Sawada Feldman, H., Lyons Jones, K., Lindsay, S., Slymen, D., Klonoff-Cohen, H., Rao, S., Chambers, C. (2012). Alcoholism: Clinical and Experimental Research, 36(4):670-676. doi: 10.1111/j.1530-0277.2011.01664.x

“Few Benefits, Significant Adverse Effects Linked With Off-Label Atypical Use" CME/CE
http://www.medscape.org/viewarticle/750980
Brauser, D. and Murata, P.
CME/CE Released: 10/05/2011; Valid for credit through 10/05/2012
Medscape Education Clinical Briefs

Target Audience: This article is intended for primary care clinicians, psychiatrists, and other specialists who provide care to adults with dementia, anxiety, and obsessive-compulsive disorder.

Goal: The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

“Increasing off-label use of antipsychotic medications in the United States, 1995-2008”
Alexander, G.C., Gallagher, S.A., Mascola, A., Moloney, R.M., & Stafford, R.S. (2011). Pharmacoepidemiology & Drug Safety, 20(2):177-184. doi: 10.1002/pds.2082.

Clinical Review: “Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults - a systematic review and meta-analysis”
Maher, A.R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., ... Shekelle, P.G. (2011). JAMA, 306(12):1359-1369. . doi: 10.1001/jama.2011.1360

“FDA: Avoid Certain Drugs When Taking Serotonergic Agents CME/CE”
http://www.medscape.org/viewarticle/747525
Lowes, R. and Barclay, L.
CME/CE Released: 08/04/2011; Valid for credit through 08/04/2012
Medscape Education: From Medscape Education Clinical Briefs

Target Audience: This article is intended for primary care clinicians, psychiatrists, infectious disease specialists, and other specialists caring for patients treated with serotonergic psychiatric medications in whom treatment with linezolid or methylene blue is being considered.

Goal: The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

“Clinicians generally should avoid prescribing either methylene blue or linezolid (Zyvox; Pfizer) in combination with serotonergic agents such as paroxetine or duloxetine to avoid a potential drug interaction causing serotonin syndrome, the FDA announced on July 26.”

Safety Announcement: “FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications”
http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm
The United States (US) Food and Drug Administration (FDA), US Department of Health & Human Service. (2011, July 26.) 

“AAP Issues Guidelines on Health Supervision of Patients With Down Syndrome CME/CE”
http://www.medscape.org/viewarticle/747163
Melville, N. and Barclay, L.
CME/CE Released: 07/29/2011; Valid for credit through 07/29/2012
Medscape Education Clinical Briefs

Target Audience: This article is intended for primary care clinicians, neurologists, cardiologists, and other specialists caring for patients with Down syndrome.

Goal: The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Clinical Report - "Health Supervision for Children With Down Syndrome”
Bull, M.J., the Committee on Genetics, American Academy of Pediatrics. (2011). Pediatrics, 128(2):393-406. doi: 10.1542/peds.2011-1605

“Trichotillomania and its Treatment: A Review and Recommendations” CME
http://www.medscape.org/viewarticle/746938
Franklin, M.E., Zagrabbe, K., & Benavides, K.L.
CME Released: 07/28/2011; Valid for credit through 07/28/2012.
Medscape Education.

Expert Review of Neurotherapeutics. (2011). 11(8):1165-1174. doi: 10.1586/ern.11.93

Target Audience: This activity is intended for primary care clinicians, pediatricians, psychiatrists, neurologists, and other healthcare practitioners caring for patients with TTM.

Goal: The goal of this activity is to review the clinical features and management of TTM.

 

DDD Home

• History
• Research Division
• Medical Students
• Awards
• News
• DDD Clinical Bulletin
• Resources
• Events
• Contact Us
• Home